How drugs are manufactured and distributed is a complicated global supply chain, with numerous drugs and their component parts manufactured in other countries. Research firm GlobalData issued a statement that the COVID-19 pandemic threatens biopharma in-house manufacturing.
Pointing at China, the report notes that the supply chain issues there includes a “largely quarantined workforce, delays in transporting materials and several other logistical hurdles. Although some Chinese factories have returned to normal capacity, others are reportedly operating at between 50% and 80% capacity.”
